128 related articles for article (PubMed ID: 29883664)
1. Preparation and Quality Evaluation of Salvianolic Acids and Tanshinones Dry Powder Inhalation.
Wang J; Zhai W; Yu J; Wang J; Dai J
J Pharm Sci; 2018 Sep; 107(9):2451-2456. PubMed ID: 29883664
[TBL] [Abstract][Full Text] [Related]
2. [Preparation and characterization of salvianolic acids-tanshinones composite powder for inhalation via co-micronized method].
Zhai WW; Dai JD; Liu LH; Huang RX; Li YJ; Mao YW; Jiang QL
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):659-665. PubMed ID: 28871689
[TBL] [Abstract][Full Text] [Related]
3. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder.
Cai X; Yang Y; Xie X; Yu F; Yang Y; Yang Z; Zhang T; Mei X
Drug Deliv; 2016 Jul; 23(6):1962-71. PubMed ID: 26066037
[TBL] [Abstract][Full Text] [Related]
5. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.
Pallagi E; Karimi K; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2016 Sep; 511(1):151-160. PubMed ID: 27386791
[TBL] [Abstract][Full Text] [Related]
6. Alternative carriers in dry powder inhaler formulations.
Rahimpour Y; Kouhsoltani M; Hamishehkar H
Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
[TBL] [Abstract][Full Text] [Related]
7. [Formulation of new generation drug delivery system for dry powder inhalation.].
Chvatal A; Szabo B; Szabo-Revesz P; Ambrus R
Acta Pharm Hung; 2016; 86(3):75-83. PubMed ID: 29489079
[TBL] [Abstract][Full Text] [Related]
8. [Recent progress of dry powder inhalation of proteins and peptides].
Zhou JY; Zhang L; Mao SR
Yao Xue Xue Bao; 2015 Jul; 50(7):814-23. PubMed ID: 26552141
[TBL] [Abstract][Full Text] [Related]
9. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
10. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
[TBL] [Abstract][Full Text] [Related]
11. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
12. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance.
Ezzati Nazhad Dolatabadi J; Hamishehkar H; Valizadeh H
Drug Dev Ind Pharm; 2015; 41(9):1431-7. PubMed ID: 25220930
[TBL] [Abstract][Full Text] [Related]
13. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
14. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
15. Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration.
Abdelbary AA; Al-mahallawi AM; Abdelrahim ME; Ali AM
Int J Nanomedicine; 2015; 10():6339-53. PubMed ID: 26491298
[TBL] [Abstract][Full Text] [Related]
16. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
17. In vitro dry powder inhaler formulation performance considerations.
Ziffels S; Bemelmans NL; Durham PG; Hickey AJ
J Control Release; 2015 Feb; 199():45-52. PubMed ID: 25497311
[TBL] [Abstract][Full Text] [Related]
18. Carrier-free high-dose dry powder inhaler formulation of ibuprofen: Physicochemical characterization and in vitro aerodynamic performance.
Yazdi AK; Smyth HDC
Int J Pharm; 2016 Sep; 511(1):403-414. PubMed ID: 27349791
[TBL] [Abstract][Full Text] [Related]
19. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
[TBL] [Abstract][Full Text] [Related]
20. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
